I n the past decade, through improved understanding of the molecular and immunologic underpinnings of cancer, new targeted therapies and immunotherapies are available to treat patients with metastatic non-small cell lung cancer (mNSCLC). Approved targeted therapies for patients with oncogenic driver mutations in EGFR (OMIM 131550), ALK (OMIM 105590), and ROS1 (OMIM 165020) result in large overall response rates (ORRs) and progression-free survival (PFS) gains over chemotherapy. [1] [2] [3] [4] [5] [6] [7] In 2015 and 2016, the US Food and Drug Administration (FDA) approved 3 immune checkpoint inhibitors (anti-PD-1 [anti-programmed cell death 1] and anti-PD-L1 [anti-programmed cell death 1 ligand 1] antibodies) for treatment of patients with mNSCLC after progression of disease during platinum-based doublet chemotherapy, and in late 2016, the FDA approved an immune checkpoint inhibitor for the first-line treatment of patients with mNSCLC and high tumor PD-L1 expression based on overall survival (OS) gains compared with chemotherapy.
8-10
The FDA also approved immune checkpoint inhibitors for the treatment of patients with advanced melanoma, squamous cell carcinoma of the head and neck, classic Hodgkin lymphoma, urothelial carcinoma, and renal cell carcinoma. The broad efficacy of the anti-PD-1 and anti-PD-L1 antibodies across various malignant neoplasms has led to unprecedented levels of research and development of these agents, along with development of novel immune-based targets.
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Despite the progress and robust development of new immunotherapies and targeted therapies in mNSCLC and other cancers, additional intermediate end points may be needed to detect signals of early activity, prioritize combinations, and interpret exploratory study results. Response and progression by conventional Response Evaluation Criteria in Solid Tumors (RECIST) may not fully characterize the clinical benefit of the immune checkpoint inhibitors. 13, 14 For example, in the all-comer second-line mNSCLC studies of anti-PD-1 and anti-PD-L1 therapy vs docetaxel, the ORR was relatively modest (approximately 15%-20%), with no improvements in PFS, but the OS was demonstrably superior. [15] [16] [17] [18] In addition, perhaps owing to the delayed effect of certain immunotherapies in some patients, the rare unconventional radiographic patterns (eg, immune cell infiltration of a tumor mimicking disease progression), and the heterogeneity of patient populations studied, the Kaplan-Meier curves of some clinical trials comparing immunotherapy with chemotherapy show nonproportionality and delayed separation. 19, 20 Thus, although most patients with mNSCLC do not appear to benefit from anti-PD-1 or anti-PD-L1 antibodies, a subset of these patients derives long-term benefit. This result may be analogous to anti-CTLA-4 therapy in metastatic melanoma, in which long-term follow-up of patients demonstrated a tail of the survival curve indicating that a subset of patients experiences long-term survival.
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The unique patterns of response, progression, and survival with immune checkpoint inhibitors in mNSCLC and other cancers have renewed interest in exploring novel intermediate end points to gain an early signal of activity and assist in go/no-go decision making. Milestone analysis, which looks at survival at a given time point, such as at 12 months, has been proposed as a potential intermediate end point for immunotherapy clinical trials. [22] [23] [24] Potential advantages of milestone analysis include its simplicity (it is time driven), it can capture effects beyond the median with delayed separation of the Kaplan-Meier curves (assuming the milestone time is beyond the median), and it may be agnostic to nonproportionality of survival curves. To further explore milestone analysis, we updated a pooled database of mNSCLC trials submitted to the FDA and compared milestone rates with more traditional oncology end points, including ORR, PFS, and OS.
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Methods
Selection Criteria
Original Analysis A previous analysis 25 identified 14 randomized clinical activecontrol trials submitted to the FDA from January 1, 2003, through December 31, 2013, 26-39 that evaluated treatments for advanced mNSCLC. Only trials with more than 150 patients and in which the intention-to-treat population was assessed were included. Associations among trial-level PFS hazard ratio (HR), OS HR, and ORR odds ratio were analyzed using weighted linear regression models.
Updated Analysis
We added 11 randomized clinical trials submitted from January 1, 2014, through December 31, 2016, [15] [16] [17] [18] [40] [41] [42] [43] [44] [45] [46] to the original pooled analysis for a total of 25 unique trials enrolling 20 013 unique patients (Table and Figure 1 ). Altogether, 4 trials were molecularly enriched for oncogene-driver mutations (EGFR mutation or ALK rearrangements) evaluating targeted therapy vs chemotherapy control, including 3 first-line trials and 1 in the second-line setting. Six trials tested immunotherapy vs chemotherapy control, including 5 that assessed immunotherapy vs docetaxel in the second-line setting and 1 that evaluated immunotherapy vs platinum-based doublet therapy in the front-line setting enriched for patients with high tumor PD-L1 expression. Fifteen trials tested various other therapies (nonmolecularly enriched targeted therapy or nonimmunotherapy) as head-to-head comparisons (n = 6) to standard of care or as an add-on to standard of care (n = 9), including 8 trials of first-line therapy and 7 trials of second-line therapy and beyond. Included in these 25 trials are a mix of positive studies (ie, leading to a new indication) and negative studies (ie, not leading to a new indication or noninferiority in design). No placebo-controlled studies were included.
Outcome Measures
Traditional End Points Overall survival was defined as the time from randomization to death. For patients alive at the data cutoff date, OS was censored at the last follow-up date. Progression-free survival was defined as the time from randomization to progression or death. Patients alive who had not experienced progression as of the analysis cutoff date were censored at the last disease assessment. In most of the trials, PFS was determined by RECIST. 47, 48 Overall response rate was defined as the proportion of patients who achieve a complete or partial response per RECIST or World Health Organization criteria. 49 Patients with unevaluable or unknown response status were considered to be nonresponders. All analyses used the intention-to-treat population, defined as all randomized patients.
Milestone Rates and Milestone Ratios
In the updated pooled analysis, we calculated the following trial-level milestone rates using Kaplan-Meier estimates: 9-month PFS, 9-month OS, and 12-month OS. Overall response rate within the first 6 months for each trial was also calculated. We chose these particular milestones because they were near or beyond the median survival of most first-or second-line trials in mNSCLC but were at a time when the number of patients censored was not too high and the number of patients remaining at risk was not too low. From the milestone rates, we calculated milestone ratios. Milestone ratio is defined as the ratio of milestone rates between 2 treatment arms. As an example of the milestone ratio, if the estimated 9-month OS milestone rate is 50% in the experimental arm and 25% in the control arm, the milestone ratio is 2. We chose milestone ratios rather than absolute differences in milestone rates because the ratio is preferred when large variability in control arm milestone rates exists, as is the case with the studies included in the meta-analysis.
Statistical Analysis Trial-Level Analysis
The associations between treatment effects on milestone rate and PFS and on milestone rate and OS were evaluated using weighted linear regression models, with analyses performed on a logarithmic scale and weights equal to the sample size of each randomized comparison. The coefficient of determination (R 2 ) and the associated 95% CIs from the weighted linear regression model were used to measure the association between milestone rate and PFS and between milestone rate and OS by treatment effect. We presented treatment effects on PFS and OS using HRs estimated from Cox proportional hazards regression models and treatment effects on milestone rates using milestone ratios.
Patient-Level Pooled Analysis
For exploratory purposes, experimental and control arms for the targeted therapies, immunotherapies, and conventional therapies were pooled. Aggregated PFS and OS survival curves by treatment arm for each of these 3 therapeutic classes were explored using Kaplan-Meier estimates.
Results
The aggregated key baseline demographic and disease characteristics of the 20 013 unique patients enrolled in the 25 unique trials are listed in eTable 1 in the Supplement. Consistent with the previous analysis, the mean patient age was 60 (range, 18-92) years, and 80.2% of patients were enrolled outside the United States. Most of the patients were white (77.2%);
18.3% were Asian; and 2.1% were black. About two-thirds of patients (65.4%) were male, and 34.6% were female.
In the 25 trials, the median follow-up for PFS was 16 months (range, 8-31 months). The median follow-up for OS was 19 months (range, 10-32 months). In general, the highest rates of ORR within 6 months, 9-month PFS, and 12-month OS were observed in the 4 targeted therapy trials [26] [27] [28] 44 (eTable 2 in the Supplement). When pooling censoring patterns across all trials, rates of censoring were highest for 9-month PFS (median, 16%; range 4%-35%), followed by 12-month OS (median, 7%; range, 1%-45%) and 9-month OS (median, 5%; range, 0.7%-27%). Figure 2 and eFigure 1 in the Supplement show the scatterplots of the treatment effects on the logarithmic scales, illustrating trial-level associations among the end points. As shown in Figure 2A , OS HR and 12-month OS milestone ratio were moderately associated (R 2 = 0.80; 95% CI, 0.63-0.91). To assess whether any trial was more influential in the trial-level association between OS HR and 12-month OS milestone ratio, a leave-one-out cross-validation by excluding 1 trial at a time was performed. The median R 2 from the cross-validation is 0.80 (range, 0.75-0.83). To assess the robustness of the findings from all 25 trials, we conducted 4 subgroup analyses, combining targeted and immunotherapies (11 comparisons), nontargeted therapies (16 comparisons), first-line studies (13 comparisons), and second-line studies (14 comparisons) (eFigure 2 in the Supplement). In this subgroup analysis, the association between OS HR and 12-month OS milestone ratio appeared to be stronger for the targeted plus immunotherapy studies (R 2 = 0.78; 95% CI, 0.51-0.93) than for nontargeted stud- Milestone ratio is calculated as the ratio of milestone rates between the experimental and control arms. A, Association between treatment effects on OS and 12-month OS rate. B, Association between treatment effects on OS and 9-month OS rate. Trials include targeted therapy trials (black), first-line nontargeted trials (orange), second-line nontargeted trials (light blue), and immunotherapy trials (dark blue).
0.0001-0.31), and modest association was observed between PFS HR and 9-month PFS milestone ratio (R 2 = 0.62; 95% CI, 0.43-0.81) (eFigure 1 in the Supplement). We found no association between treatment effect on OS as measured by HR and ORR odds ratio (R 2 = 0.04; 95% CI, 0.0002-0.28) (eFigure 3A in the Supplement), which is consistent with the results reported in the previous analysis. 25 The association between PFS as measured by HR and ORR as measured by odds ratio (R 2 = 0.74; 95% CI, 0.55-0.88) (eFigure 3B in the Supplement) was moderate but weaker than in the prior analysis 25 likely because of the addition of the 6 immunotherapy trials in which the association between ORR and PFS appeared to be weaker than with targeted therapy. The association between PFS HR and 6-month ORR milestone ratio was moderate (R 2 = 0.70; 95% CI, 0.50-0.84) (eFigure 3C in the Supplement). We pooled data from the 6 immunotherapy trials, the 4 targeted therapy trials, and the 15 conventional therapy trials and performed Kaplan-Meier analysis of treatment arm vs control. Each therapeutic class had different survival kinetics with respect to PFS and OS. Figure 3 depicts the OS curves. With the immunotherapy trials, the pooled OS curves appeared to separate after about 3 months and remain separated at 12, 18, and 24 months. The estimated median of OS for the immunotherapy-and chemotherapy-treated patients in this pooled analysis were 12 and 9 months, respectively (HR, 0.69; 95% CI, 0.63-0.75). In the targeted therapy trials, no separation of the OS curves between targeted therapy and control arms was discerned likely owing to high rates of crossover from the chemotherapy groups to the targeted therapy groups and the long postprogression survival time; the estimated median survival among those receiving targeted therapy was 27 months (HR, 0.98; 95% CI, 0.80-1.19). In the conventional therapy trials (a mix of positive and negative, first-and later-line, and superiority and noninferiority trials), no separation could be discerned between experimental and treatment arms and the estimated median survival was 9 months (HR, 0.92; 95% CI, 0.89-0.96). Figure 4 depicts the exploratory pooled PFS curves by therapeutic class. For the immunotherapy trials, the PFS curves separated at approximately 6 months and a fraction of patients were progression free at 12 and 18 months (HR, 0.82; 95% CI, 0.76-0.89). In contrast, in the targeted therapy trials, the PFS curves separated early, with a fraction of patients progression free at 12, 18, and 24 months (HR, 0.48; 95% CI, 0.42-0.56). In the standard-of-care studies (a heterogeneous mix of studies), no clear separation in the PFS curves could be discerned (HR, 0.90; 95% CI, 0.87-0.93).
Discussion
We explored milestone analysis for several reasons. First, traditional metrics of response and progression by RECIST may not be sufficient for signal finding or for prioritizing combinations of immunotherapies. For example, in all-comer secondline mNSCLC trials (not enriched based on presence of PD-L1 expression), the relatively modest ORR and absent PFS effects were not predictive of the survival gains achieved with anti-PD-1 and anti-PD-L1 agents vs docetaxel. 15-18 Second, patients treated with immunotherapy agents such as anti-PD-1 and anti-PD-L1 therapies demonstrate unique patterns of response, progression, and survival. On a population level, these patterns can lead to delayed separation of survival curves beyond the median, nonproportional curves, and a subset of patients potentially deriving longterm benefit. On a trial level, this exploratory analysis of milestone ratios suggests a moderate association between the OS milestone ratio at 12 months and OS HR (R 2 = 0.80) and modest associations between the OS milestone ratio at 9 months and OS HR (R 2 = 0.67), 6-month ORR odds ratio and PFS HR (R 2 = 0.70), and the PFS milestone ratio at 9 months and PFS HR (R 2 = 0.62). No associations were observed between the PFS milestone ratio at 9 months and OS HR or between the ORR milestone ratio at 6 months and OS HR. Therefore, in the present database of trials, the OS milestone ratio at 12 months had the strongest association with OS HR and could be explored prospectively as a secondary end point in mNSCLC trials or used to interpret or analyze study results for go/no-go decisions.
A specific milestone such as 12-month OS, while moderately associated with OS in our present database, may not be as strongly associated with OS HR in future trials. The optimal time point for milestone analysis may depend on the patient population studied (all-comer vs oncogene-or other marker-driven), the disease context (first-line vs later-line treatment), the therapeutic class of drug or drugs being studied (targeted vs immunotherapy vs cytotoxic chemotherapy or a combination thereof), the control arm being studied, and the magnitude of effect sought (incremental vs large or superiority vs noninferiority).
Use of the milestone rate as a clinical trial end point has several limitations, including the inability to account for the totality of the survival curve and the effect of censoring before the milestone time point. Milestones should not be thought of as conventional surrogate end points, given the significant overlap between a survival milestone and the ultimate clinical end point, OS HR. Milestone analyses may have advantages, which include predictability (being time driven rather than event driven) and simplicity of analysis. The outcome (such as survival) can be clinically meaningful, and relative and absolute differences in treatment effect can be assessed in the context of a randomized clinical trial. Furthermore, milestones (if measured at a mature time point) may be agnostic to whether the survival curves separate late or are nonproportional. Mature milestone rates may also capture subsets of patients who derive longer-term benefit.
The pooling of immunotherapy trials, targeted therapy trials, and conventional therapy trials to explore KaplanMeier estimates of OS and PFS showed that each therapeutic class had unique properties. In trials comparing immunotherapy with chemotherapy, there appeared to be delayed separation of PFS and OS curves, with improvement over chemotherapy, in OS (HR, 0.69; 95% CI, 0.63-0.75) and, to a lesser 
Conclusions
We found moderate associations between the milestone rate of OS at 12 months and OS HR but no associations with other milestone rates, such as PFS at 9 months and OS HR. Although the milestone rate should not be used as a primary intermediate end point for a pivotal study, it could be prospectively incorporated as a secondary end point for future exploratory studies, particularly those testing immunotherapy combinations vs immunotherapy alone. For a primary end point in a randomized clinical trial using a time-to-event end point, the log-rank test is preferred to detect whether an effect exists. Milestone analysis could be used as a complementary tool to describe and analyze study results, along with more conventional measures such as ORR, duration of response, PFS, and OS, as well as other less established metrics such as tumor growth rates and depth of response. 50,51 Whether our findings in mNSCLC can be generalized to other cancer types should also be explored. In addition, further research into other methods that potentially address nonproportionality should be investigated to better account for therapeutic effects on long-term survival that may be observed in immunotherapy trials. 
